Mucositis management in patients with cancer

Supportive Cancer Therapy

Volumn 3, Issue 3, 2006, Pages 154-157

  Keefe, Dorothy M K ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Gastrointestinal mucositis; Oral mucositis; Toxicity; Ulceration

Indexed keywords

AMIFOSTINE; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; DOXORUBICIN; FLUOROURACIL; HISTAMINE H2 RECEPTOR ANTAGONIST; IRINOTECAN; LOPERAMIDE; MELPHALAN; METHOTREXATE; OCTREOTIDE; PALIFERMIN; PROTON PUMP INHIBITOR;

ANOREXIA; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE SEVERITY; DISTRESS SYNDROME; DOWN REGULATION; DRUG HALF LIFE; DRUG MEGADOSE; FATIGUE; GASTROINTESTINAL TRACT; GENETIC PREDISPOSITION; HEALTH CARE COST; HEMATOLOGIC MALIGNANCY; HUMAN; MOUTH PAIN; MOUTH ULCER; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; PREDICTION; QUALITY OF LIFE; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; SKIN DEFECT; SOLID TUMOR; UPREGULATION; XEROSTOMIA;

EID: 33745768599     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2006.n.013     Document Type: Review

References (17)

1. Abeloff M, Armitage J, Niederhuber J, et al. Clinical Oncology. 3rd ed. Elsevier (Churchill Livingstone); 2003.
2. Embryology of the gut. In: Larsen WJ, ed. Essentials of Human Embryology. 2nd ed. Elsevier (Churchill Livingstone); 1998:229-260.
3. Keefe DMK. The effect of cytotoxic chemotherapy on the mucosa of the small intestine [doctorate thesis]. South Australia: University of Adelaide; 1999.
4. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology and consequences for patients. Cancer 2004; 100(suppl 9):1995-2025.
5. Keefe DMK. Gastrointestinal mucositis: a new biological model. Supportive Care Cancer 2004; 23:6-9.
6. Keefe DMK, Gibson RJ, Hauer-Jensen M. Gastrointestinal mucositis. Semin Oncol Nurs 2004; 20:38-47.
7. Elting LS, Keefe DMK, Sonis ST. Treatment-induced gastrointestinal toxicity in patients with cancer. ASCO Educational Booklet 2004; 536-541.
8. Keefe DMK, Cummins AG, Dale BM, et al. The effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci 1997; 92:385-389.
9. Radiation sources, geometry, exposure schedule, and effect quantitation for irradiation of the gut. In: Potten CS, Hendry, eds. Radiation and Gut. Elsevier; 1995.
10. Ijiri K, Potten C. Response of intestinal cells of differing topographical and hierarchical status to ten cytotoxic drugs and five sources of radiation. Br J Cancer 1983; 47:175-185.
11. Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 100(suppl 9):2026-2046.
12. Spielberger R, Stiff P, Bensinger W, et al. A phase 3, randomized, double-blind, placebo-controlled trial of palifermin for reduction of mucositis in patients with hematologic malignancies undergoing TBI with high-dose chemotherapy with auto-PBPCT. N Engl J Med 2004; 351:2590-2598.
13. Gibson RJ, Bowen JM, Keefe DMK. Palifermin reduces diarrhea and increases survival following Irinotecan treatment in tumour-bearing DA rats. Int J Cancer 2005; 116:464-470.
14. Dorr W, Reichel S, Spekl K. Effects of keratinocyte growth factor (palifermin) administration protocols on oral mucostitis (mouse) induced by fractionated irradiation. Radiother Oncol 2005; 75:99-105.
15. Peterson DE, Petit RG. Phase III study: AES-14 in patients at risk for mucositis secondary to anthracycline-based chemotherapy. Proc Am Soc Clin Oncol 2004; 22:2917 (Abstract #8008).
16. Schuster MW, Shore TB, Greenberg J, et al. Phase I trial of CG53135-05 to prevent mucositis in patients undergoing high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplantation (PBSCT). J Clin Oncol 2005; 23(suppl 16):599s (Abstract #6656).
17. MASCC mucositis management guidelines update. Available at: www. mascc.org. Accessed August 30, 2005.